Business Context and Reporting Period
This Form 8-K filing by GlycoMimetics, Inc. (not Crescent Biopharma, Inc.) reports on the results of the 2015 Annual Meeting of Stockholders held on July 15, 2015. The filing details the voting outcomes for director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 19,017,133 shares outstanding, 17,053,758 shares (89.7%) were present or represented by proxy. The following proposals were approved:
- Proposal 1: Election of Directors
- Rachel K. King: 12,234,400 votes For; 476,828 votes Withheld.
- Michael A. Henos: 12,209,580 votes For; 501,648 votes Withheld.
- Broker Non-Votes: 4,342,530.
- Both nominees were elected to serve until the 2018 annual meeting.
- Proposal 2: Ratification of Auditor
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2015.
- Votes For: 17,048,355
- Votes Against: 5,313
- Abstained: 90
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Important Facts for Investors to Verify
- Confirm the company name is GlycoMimetics, Inc., as the metadata reference to "Crescent Biopharma, Inc." appears to be an error in the request context.
- Verify the high level of broker non-votes (4,342,530) relative to the total shares outstanding.
- Review the definitive proxy statement filed on June 15, 2015, for detailed background on the director nominees and auditor appointment.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.